Streetbeat News

Products Services

JNJ

Johnson & Johnson has submitted an FDA application for a fixed combination of Amivantamab and Recombinant Human Hyaluronidase for subcutaneous administration. This combination is intended for all currently approved or submitted indications of IV Rybrevant in certain types of non-small cell lung cancer (NSCLC).

Portfolio Pulse from Benzinga Newsdesk

June 17, 2024 | 12:04 pm

AVGO

CSCO

MRVL

NVDA

Broadcom Inc. (NASDAQ: AVGO) is making significant strides in the datacenter and AI Ethernet switching market, holding an 80% market share. JPMorgan analyst Harlan Sur highlights Broadcom's innovation with its Tomahawk series, which is ahead of competitors like Nvidia, Marvell, and Cisco. Broadcom's AI networking silicon revenues are expected to triple in 2024, driven by the upcoming Tomahawk 6 chipset. The company is also working on the 2nm Tomahawk 7, ensuring it stays ahead in the market.

Portfolio Pulse from Surbhi Jain

June 17, 2024 | 12:04 pm

BOF

BranchOut Food Inc. (NASDAQ:BOF) has secured a 10kW Radiant Energy Vacuum (REV) machine from EnWave Corporation for its new facility in Peru. This machine will aid in R&D, product development, and production scale-up, supporting orders valued at over $9M from major retailers.

Portfolio Pulse from Benzinga Newsdesk

June 17, 2024 | 12:04 pm

SLRX

Salarius Pharmaceuticals announced that MD Anderson Cancer Center presented clinical data on seclidemstat for MDS and CMML at the 2024 European Hematology Association Congress. The Phase 1/2 study showed a 43% overall response rate among 14 patients, with a median overall survival of 18.5 months and median event-free survival of 7.2 months.

Portfolio Pulse from Benzinga Newsdesk

June 17, 2024 | 12:03 pm

ELUT

Elutia has received FDA clearance for EluPro, the only drug-eluting biologic envelope in the $600 million U.S. implantable electronic device protection market. EluPro is also cleared for use with neurostimulators and neuromodulators for various medical conditions.

Portfolio Pulse from Benzinga Newsdesk

June 17, 2024 | 12:03 pm

ASMB

GILD

Assembly Biosciences has announced $12.6 million in equity financings through the issuance of 634,500 shares of its common stock and warrants to Armistice Capital LLC. The funding will support the advancement of its antiviral portfolio and extend its cash runway into Q1 2026. Key upcoming data readouts include ABI-5366 Phase 1a in 3Q24 and Phase 1b in 1H25, and ABI-4334 Phase 1b by the end of 2024.

Portfolio Pulse from Benzinga Newsdesk

June 17, 2024 | 12:02 pm

XPEV

XPeng Inc. (NYSE:XPEV) has successfully launched its flying car, the X2, in Beijing, marking a significant step towards commercialization by the end of the year. This development aligns with China's focus on the low-altitude economy, projected to surpass $138 billion by 2026.

Portfolio Pulse from Rounak Jain

June 17, 2024 | 11:56 am

GRFS

Grifols shares are trading higher after the company's Biotest received FDA approval for Yimmugo immunoglobulin to treat primary immunodeficiencies.

Portfolio Pulse from Benzinga Newsdesk

June 17, 2024 | 11:48 am

QGEN

Qiagen's CEO announced that the company is reviewing its smaller, low-margin products, with an update expected later this year.

Portfolio Pulse from Benzinga Newsdesk

June 17, 2024 | 11:45 am

ZYME

Zymeworks shares are trading higher following the FDA's clearance of the company's Investigational New Drug application for Zw171, targeting mesothelin-expressing cancers. Clinical development is expected to begin in 2024.

Portfolio Pulse from Benzinga Newsdesk

June 17, 2024 | 11:45 am